During the past decade, Centro Cardiologico Monzino conducted 79 clinical trials. In the 10-year time frame, 79 clinical trials started and 33 clinical trials were completed, i.e. on average, 41.8% percent of trials that started reached the finish line to date. In the past 5 years, 41 clinical trials started and 23 clinical trials were completed. i.e. 56.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centro Cardiologico Monzino" #1 sponsor was "Abbott Medical Devices" with 21 trials, followed by "Centro Cardiologico Monzino" with 18 trials sponsored, "Boehringer Ingelheim" with 7 trials sponsored, "Boston Scientific Corporation" with 5 trials sponsored and "Amgen" with 5 trials sponsored. Other sponsors include 62 different institutions and companies that sponsored additional 57 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centro Cardiologico Monzino" #1 collaborator was "Eli Lilly and Company" with 5 trials as a collaborator, "GE Healthcare" with 4 trials as a collaborator, "Abbott" with 3 trials as a collaborator, "Centro Cardiologico Monzino" with 3 trials as a collaborator and "HeartFlow, Inc." with 2 trials as a collaborator. Other collaborators include 32 different institutions and companies that were collaborators in the rest 39 trials.

According to Clinical.Site data, the most researched conditions in "Centro Cardiologico Monzino" are "Coronary Artery Disease" (22 trials), "Atrial Fibrillation" (15 trials), "Heart Failure" (14 trials), "Cardiovascular Diseases" (5 trials) and "Coronary Artery Stenosis" (5 trials). Many other conditions were trialed in "Centro Cardiologico Monzino" in a lesser frequency.

Most popular intervention types in "Centro Cardiologico Monzino" are "Device" (51 trials), "Drug" (45 trials), "Procedure" (12 trials), "Other" (8 trials) and "Diagnostic Test" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (16 trials), "Empagliflozin" (5 trials), "Evolocumab" (3 trials), "Tirzepatide" (3 trials) and "Apixaban" (2 trials). Other intervention names were less common.

The vast majority of trials in "Centro Cardiologico Monzino" are 120 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Centro Cardiologico Monzino". 1 are not yet recruiting, 15 are recruiting, 15 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 64 completed trials in Centro Cardiologico Monzino, 1 suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Centro Cardiologico Monzino, 1 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 27 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 14 trials, and there were also 34 trials that are defined as “Not Applicable".

Centro Cardiologico Monzino has several departments that took part in Clinical trials: "Centro Cardiologico Monzino - Terapia Intensiva Cardiologica (Utic)" - 5 trials